Aerie Pharmaceuticals Announces Public Offering of Common Stock
January 23 2018 - 4:03PM
Business Wire
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
patients with glaucoma or ocular hypertension and other diseases of
the eye, today announced that it has commenced a registered
underwritten public offering of $75 million of shares of its common
stock. The underwriter will have a 30-day option from the date of
the offering to purchase up to an additional $11.25 million of
shares of common stock.
Cantor Fitzgerald & Co. is acting as the sole bookrunner for
the offering.
Aerie intends to use the net proceeds of the offering for
general corporate purposes, including to fund expansion of its
commercialization programs in North America for both Rhopressa® and
Roclatan™, its clinical and commercialization efforts beyond North
America, further development of other potential pipeline
opportunities, including activities to support the ongoing
development of its retina programs and evaluating possible uses of
its existing proprietary portfolio of molecules beyond
ophthalmology, its external business development efforts, and its
manufacturing activities, including the construction of its own
manufacturing plant in Ireland.
A shelf registration statement relating to the shares is
effective with the Securities and Exchange Commission. The shares
may be offered only by means of the prospectus forming a part of
the effective registration statement and a related prospectus
supplement. A preliminary prospectus supplement related to the
offering will be filed with the Securities and Exchange Commission
today. An electronic copy of the preliminary prospectus supplement
and the accompanying prospectus will be available on the website of
the Securities and Exchange Commission at www.sec.gov. Copies of
the preliminary prospectus supplement and the final prospectus
supplement, when available, and the accompanying prospectus may be
obtained by contacting Cantor Fitzgerald & Co., Attention:
Capital Markets, 499 Park Ave., 6th Floor, New York, New York
10022, or by e-mail at prospectus@cantor.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities of Aerie, and shall
not constitute an offer, solicitation or sale of any security in
any state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with glaucoma or ocular
hypertension and other diseases of the eye.
Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “estimates,” “anticipates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “will,” “should,” “exploring,”
“pursuing” or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding our
expectations related to the offering discussed in this press
release, including the completion, timing and size of the offering
and the use of proceeds therefrom. By their nature, forward-looking
statements involve risks and uncertainties because they relate to
events and other factors beyond our control. We discuss many of
these risks in greater detail under the heading “Risk Factors” in
the quarterly and annual reports that we file with the Securities
and Exchange Commission (SEC). Any forward-looking statements that
we make in this press release speak only as of the date of this
press release. We assume no obligation to update our
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180123006482/en/
Aerie PharmaceuticalsRichard Rubino,
908-947-3540rrubino@aeriepharma.comorBurns McClellan, Inc., on
behalf of Aerie PharmaceuticalsInvestorsAmi Bavishi,
212-213-0006abavishi@burnsmc.comorMediaJustin Jackson,
212-213-0006jjackson@burnsmc.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Apr 2023 to Apr 2024